Arrow Capital’s Bristol-Myers Squibb BMY Stock Holding History

Arrow Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-58,822	Closed	-$4.16M	–	31
2025 Q2	$4.16M	Buy	+58,822	New	+$2.89M	2.01%	25

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arrow Capital's BMY Position: Q3 2025 in Review

Arrow Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2025, closing a stake of 58,822 shares — an estimated $4.16M sold.

Arrow Capital first reported a position in BMY in Q2 2025 and held it in 1 quarter. The position peaked at $4.16M in Q2 2025. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

Arrow Capital reported no remaining Bristol-Myers Squibb position as of Q3 2025 after selling out during the quarter.
Arrow Capital sold 58,822 Bristol-Myers Squibb shares in Q3 2025, an estimated $4.16M.
Arrow Capital first reported a position in Bristol-Myers Squibb in Q2 2025 and held it in 1 quarter.
Arrow Capital's Bristol-Myers Squibb position peaked at $4.16M in Q2 2025.
2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on Arrow Capital's 13F filing for Q3 2025, filed 14 Nov 2025.